Johnson & Johnson (NYSE:JNJ) Stock Position Raised by Miracle Mile Advisors LLC

Posted by Defense World Staff on Apr 1st, 2023

Miracle Mile Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 115.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 40,029 shares of the company’s stock after buying an additional 21,467 shares during the quarter. Miracle Mile Advisors LLC’s holdings in Johnson & Johnson were worth $7,071,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Veracity Capital LLC increased its holdings in Johnson & Johnson by 1.2% during the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after buying an additional 59 shares during the last quarter. Sandy Cove Advisors LLC increased its holdings in Johnson & Johnson by 1.6% during the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after buying an additional 60 shares during the last quarter. Paces Ferry Wealth Advisors LLC increased its holdings in Johnson & Johnson by 0.7% during the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after buying an additional 62 shares during the last quarter. Mason & Associates Inc increased its holdings in Johnson & Johnson by 4.9% during the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after buying an additional 62 shares during the last quarter. Finally, Magnolia Capital Advisors LLC increased its holdings in Johnson & Johnson by 0.7% during the third quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock worth $1,451,000 after buying an additional 62 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. SVB Leerink decreased their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Guggenheim assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target on the stock. Citigroup upped their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Piper Sandler dropped their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, UBS Group initiated coverage on Johnson & Johnson in a research note on Tuesday. They issued a “neutral” rating and a $164.00 price objective for the company. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $173.67.

Johnson & Johnson Trading Up 1.0 %

Shares of JNJ opened at $155.00 on Friday. The business’s 50-day moving average price is $158.02 and its 200-day moving average price is $167.12. The stock has a market cap of $403.66 billion, a PE ratio of 23.00, a P/E/G ratio of 2.64 and a beta of 0.54. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. During the same period in the previous year, the business earned $2.13 earnings per share. The firm’s quarterly revenue was down 4.4% compared to the same quarter last year. On average, equities analysts forecast that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.92%. Johnson & Johnson’s payout ratio is 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.